COMMUNIQUÉS West-GlobeNewswire

Gaylord Specialty Healthcare Appoints Dr. Jennifer Russo as Director, Inpatient Acquired Brain Injury Service, Strengthening National Expertise in Stroke and Brain Injury Rehabilitation
14/07/2026
Wallingford, CT, July 14, 2026 (GLOBE NEWSWIRE) -- Gaylord Specialty Healthcare , one of the nation's leading rehabilitation-focused healthcare systems and a recognized destination for stroke rehabilitation and [...]
AscellaHealth Named ACAP Preferred Vendor to Advance Specialty Pharmacy Strategy, Cost Containment and Care Management
14/07/2026
BERWYN, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces it has been named as a Preferred Vendor [...]
Applied Biologics Announces Successful Manufacture of First Research Construct for Disease-Modifying Osteoarthritis Gene Therapy Program
14/07/2026
SCOTTSDALE, Ariz., July 14, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
IBA – Information Réglementée
14/07/2026
Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et [...]
Inner Voyage Recovery Center earns BBB accreditation and A+ rating after eight years serving the Atlanta region
14/07/2026
Woodstock drug and alcohol rehab adds Better Business Bureau accreditation to its existing credentials — a reflection of nearly a decade of transparent, accountable care for individuals and families across Georgia [...]
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
14/07/2026
Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12- [...]
Smile Doctors Outpaces First-Half Growth Plan, Nears 600 Locations Nationwide
14/07/2026
Entering its second decade, the nation's largest ortho-focused support organization posts double-digit first-half growth as new orthodontist affiliations, de novo expansion and accelerating adult demand continue to [...]
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. [...]
Visory Health Wins a Digital Health Award for Second Consecutive Year
14/07/2026
The win recognizes the app for its real-time pricing and digital Rx savings card, which help users cut prescription costs by up to 80% - no insurance or coupons required ESTERO, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- [...]
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026
Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than 30% as Pluri advances its longevity and U.S. [...]
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
14/07/2026
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents SARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or [...]
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14/07/2026
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No [...]
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
14/07/2026
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo. The LiBBY study [...]
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
14/07/2026
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding [...]
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
14/07/2026
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, [...]
SS Innovations Appoints Sarah M. Romano as Chief Financial Officer
14/07/2026
Veteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth FORT LAUDERDALE, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- via IBN -- [...]
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
14/07/2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
14/07/2026
Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT 2C ) pharmacodynamics approved in its FDA product labeling. Qelbree has [...]
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
14/07/2026
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering IRVINE, Calif., July 14, 2026 ( [...]

Pages